Literature DB >> 7682986

Construction of a reshaped HMFG1 antibody and comparison of its fine specificity with that of the parent mouse antibody.

M E Verhoeyen1, J A Saunders, M R Price, J D Marugg, S Briggs, E L Broderick, S J Eida, A T Mooren, R A Badley.   

Abstract

A human antibody with milk mucin specificity was obtained by transferring the complementarity determining regions (CDR) of the mouse antibody HMFG1 onto carefully selected human framework regions. The resulting reshaped human antibody, HuHMFG1, showed no difference in relative affinity for its antigen compared with the parent mouse HMFG1. The minimum epitope recognized by both the mouse and reshaped antibodies was demonstrated by epitope mapping to be identical, and consists of the tetramer PDTR. In a replacement net analysis, in which each of the amino acids was replaced in turn with the 19 other residues, it was determined that mouse HMFG1 and HuHMFG1 reacted with this series of synthetic peptides in an equivalent manner, indicating retention of identical fine specificity in the HuHMFG1 antibody. In contrast to other published reports, this was achieved without involvement of any framework residues in the binding site transfer. These data demonstrate that if well-matching human framework regions are employed grafting the CDR only can be sufficient to confer desired specificities to human antibodies and can, indeed, provide human analogues of mouse antibodies with virtually indistinguishable affinities and fine specificities relative to the mouse parent antibodies.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7682986      PMCID: PMC1421827     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  28 in total

1.  Development and characterization of breast cancer reactive monoclonal antibodies directed to the core protein of the human milk mucin.

Authors:  J Burchell; S Gendler; J Taylor-Papadimitriou; A Girling; A Lewis; R Millis; D Lamport
Journal:  Cancer Res       Date:  1987-10-15       Impact factor: 12.701

2.  Replacing the complementarity-determining regions in a human antibody with those from a mouse.

Authors:  P T Jones; P H Dear; J Foote; M S Neuberger; G Winter
Journal:  Nature       Date:  1986 May 29-Jun 4       Impact factor: 49.962

3.  Crystal and molecular structure of a dimer composed of the variable portions of the Bence-Jones protein REI.

Authors:  O Epp; P Colman; H Fehlhammer; W Bode; M Schiffer; R Huber; W Palm
Journal:  Eur J Biochem       Date:  1974-06-15

4.  A simple and very efficient method for generating cDNA libraries.

Authors:  U Gubler; B J Hoffman
Journal:  Gene       Date:  1983-11       Impact factor: 3.688

5.  Cloned human and mouse kappa immunoglobulin constant and J region genes conserve homology in functional segments.

Authors:  P A Hieter; E E Max; J G Seidman; J V Maizel; P Leder
Journal:  Cell       Date:  1980-11       Impact factor: 41.582

6.  Structure of human immunoglobulin gamma genes: implications for evolution of a gene family.

Authors:  N Takahashi; S Ueda; M Obata; T Nikaido; S Nakai; T Honjo
Journal:  Cell       Date:  1982-06       Impact factor: 41.582

7.  Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture.

Authors:  J Taylor-Papadimitriou; J A Peterson; J Arklie; J Burchell; R L Ceriani; W F Bodmer
Journal:  Int J Cancer       Date:  1981-07-15       Impact factor: 7.396

8.  Structural and computational investigations of the conformation of antigenic peptide fragments of human polymorphic epithelial mucin.

Authors:  M J Scanlon; S D Morley; D E Jackson; M R Price; S J Tendler
Journal:  Biochem J       Date:  1992-05-15       Impact factor: 3.857

9.  Human immune response to multiple injections of murine monoclonal IgG.

Authors:  D L Shawler; R M Bartholomew; L M Smith; R O Dillman
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

10.  Construction, expression and characterization of humanized antibodies directed against the human alpha/beta T cell receptor.

Authors:  C W Shearman; D Pollock; G White; K Hehir; G P Moore; E J Kanzy; R Kurrle
Journal:  J Immunol       Date:  1991-12-15       Impact factor: 5.422

View more
  9 in total

Review 1.  Cancer-associated mucins: role in immune modulation and metastasis.

Authors:  Rakesh Bhatia; Shailendra K Gautam; Andrew Cannon; Christopher Thompson; Bradley R Hall; Abhijit Aithal; Kasturi Banerjee; Maneesh Jain; Joyce C Solheim; Sushil Kumar; Surinder K Batra
Journal:  Cancer Metastasis Rev       Date:  2019-06       Impact factor: 9.264

Review 2.  Improving theranostics in pancreatic cancer.

Authors:  Jeremy King; Michael Bouvet; Gagandeep Singh; John Williams
Journal:  J Surg Oncol       Date:  2017-05-17       Impact factor: 3.454

3.  In vitro and in vivo antitumor activity of a chimeric anti-CD19 antibody.

Authors:  G A Pietersz; L Wenjun; V R Sutton; J Burgess; I F McKenzie; H Zola; J A Trapani
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

4.  Rise and fall of an anti-MUC1 specific antibody.

Authors:  Holger Thie; Lars Toleikis; Jiandong Li; Reinhard von Wasielewski; Gunther Bastert; Thomas Schirrmann; Isabel Tourais Esteves; Christian K Behrens; Bénédict Fournes; Nathalie Fournier; Christophe de Romeuf; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

5.  Characterisation and internalisation of recombinant humanised HMFG-1 antibodies against MUC1.

Authors:  L M Pericleous; J Richards; A A Epenetos; N Courtenay-Luck; M P Deonarain
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

6.  Axillary node status in breast cancer patients prior to surgery by imaging with Tc-99m humanised anti-PEM monoclonal antibody, hHMFG1.

Authors:  A R Al-Yasi; M J Carroll; D Ellison; M Granowska; S J Mather; C A Wells; R Carpenter; K E Britton
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

7.  A transgenic mouse model for tumour immunotherapy: induction of an anti-idiotype response to human MUC1.

Authors:  R W Wilkinson; E L Ross; A E Lee-MacAry; R Laylor; J Burchell; J Taylor-Papadimitriou; D Snary
Journal:  Br J Cancer       Date:  2000-11       Impact factor: 7.640

8.  Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer.

Authors:  Mark D Pegram; Virginia F Borges; Nuhad Ibrahim; Jyotsna Fuloria; Charles Shapiro; Susan Perez; Karen Wang; Franziska Schaedli Stark; Nigel Courtenay Luck
Journal:  Breast Cancer Res       Date:  2009       Impact factor: 6.466

9.  Impact of antibody framework residue VH-71 on the stability of a humanised anti-MUC1 scFv and derived immunoenzyme.

Authors:  J Krauss; M A E Arndt; Z Zhu; D L Newton; B K Vu; V Choudhry; R Darbha; X Ji; N S Courtenay-Luck; M P Deonarain; J Richards; S M Rybak
Journal:  Br J Cancer       Date:  2004-05-04       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.